New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
10:00 EDTMGM, RES, JASO, NOW, RGP, CNAT, CJES, AMCC, TRI, CRM, LADR, MGA, NEWM, TEP, RSE, JAZZ, BBNKOn The Fly: Analyst Initiation Summary
Bridge Capital Holdings (BBNK) initiated with a Buy at DA Davidson... Conatus Pharmaceuticals (CNAT) initiated with a Buy at Roth Capital... E2open (EOPN) initiated with a Buy at B. Riley... Jazz Pharmaceuticals (JAZZ) reinstated with an Overweight at Barclays... Ladder Capital (LADR) initiated with a Buy at Deutsche Bank... Regency Energy Partners (RGP) initiated with a Hold at Deutsche Bank... Rouse Properties (RSE) initiated with a Neutral at BofA/Merrill... Salesforce.com (CRM) initiated with a Neutral at B. Riley... ServiceNow (NOW) initiated with a Neutral at B. Riley... Tallgrass Energy (TEP) initiated with an Outperform at Wells Fargo... Thomson Reuters (TRI) initiated with a Hold at Deutsche Bank... JA Solar (JASO) initiated with a Buy at Sidoti... Applied Micro Circuits (AMCC) initiated with a Buy at Roth Capital... New Media (NEWM) initiated with a Buy at Compass Point... Magna (MGA) initiated with a Buy at TD Securities... RPC, Inc. (RES) initiated with a Buy at ISI Group... C&J Energy (CJES) initiated with a Strong Buy at ISI Group... MGM Resorts (MGM) initiated with a Buy at Ascendiant.
News For BBNK;CNAT;JAZZ;LADR;RGP;RSE;CRM;NOW;TEP;TRI;JASO;NEWM;AMCC;RES;MGA;CJES;MGM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 2, 2015
08:29 EDTMGMUBS shifts from cautious stance on Macau gaming after policy change
UBS said it is taking a more constructive stance on of Macau gaming names sector as it believes the recent visa policy change lowers fears on further local tightening. The firm also cited the lowered risk of large scale downgrades in the sector and valuations that support the sector, though it noted that larger upside depends on an earnings upgrade cycle. UBS said it is unattractive to take a negative sector position given the backdrop. Publicly traded companies in the Macau gaming space include Las Vegas Sands (LVS), MGM Resorts (MGM), Melco Crown (MPEL) and Wynn Resorts (WYNN).
July 1, 2015
07:30 EDTJASODrop is Solar stocks a buying opportunity, says Deutsche Bank
Deutsche Bank analyst Vishal Shah attributes the recent weakness in the Solar space to investor concerns around increased interest rate and growth uncertainty, especially of YieldCos. Shah, however, views YieldCos as a significant growth catalyst for the solar and broader renewables sector. The analyst expects the current weakness to provide an attractive entry point for longer term investors. Publicly traded companies in the space include Canadian Solar (CSIQ), First Solar (FSLR), JA Solar (JASO), SunPower (SPWR), Trina Solar (TSL) and Yingli Green Energy (YGE).
06:48 EDTMGMMacau reports June casino revenue down 36.2% to 17.36B patacas
Subscribe for More Information
June 30, 2015
15:17 EDTMGMMacau visa change does not signal a change in policy, says Wells Fargo
Subscribe for More Information
12:59 EDTCRMSalesforce management to meet with UBS
Subscribe for More Information
12:50 EDTMGMMacau transit visa rules reversed, signal end of tightening, says BofA/Merrill
Subscribe for More Information
12:44 EDTMGMMacau appears to re-lengthen visas to 7 days, says Brean Capital
Subscribe for More Information
10:01 EDTTEPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTRESOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:13 EDTRESRPC, Inc. upgraded to Neutral from Sell at Citi
Subscribe for More Information
June 29, 2015
17:08 EDTTEPTallgrass Energy initiated with a Buy at Evercore ISI
Subscribe for More Information
10:09 EDTRSEOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:10 EDTJAZZJazz Pharmaceuticals price target raised to $210 from $190 at UBS
UBS raised its price target on Jazz Pharmaceuticals to $210 from $190 on expectations for Xyrem sales growth, its lower tax rate and its strong balance sheet. UBS reiterated its Buy rating on Jazz Pharmaceuticals shares.
05:59 EDTRSERouse Properties initiated with an Overweight at Barclays
Subscribe for More Information
June 28, 2015
16:00 EDTCRMFormer Salesforce CFO Graham Smith to depart June 30
Subscribe for More Information
12:47 EDTCRMTech sector earnings 'melt away' when accounting for stock comp, Barron's says
Subscribe for More Information
June 26, 2015
09:32 EDTMGMNevada reports May Statewide gaming win up 3.33% to $1.0B
Subscribe for More Information
June 25, 2015
07:09 EDTCNATConatus announces initial baseline data from Phase 2b POLT-HCV-SVR trial
Conatus announced pre-treatment biomarker and histology data from the first 16 patients enrolled in the company's Phase 2b clinical trial of its lead drug candidate, emricasan, in post-orthotopic liver transplant, or POLT, recipients. These patients have reestablished liver fibrosis or cirrhosis post-transplant as a result of recurrent hepatitis C virus, or HCV, infection and have successfully achieved a sustained viral response, or SVR, following HCV antiviral therapy, or POLT-HCV-SVR. Among the first 16 patients enrolled, more than 85% achieved SVRs using recently approved oral HCV antiviral treatments. The excitement generated by these new treatments altered enrollment patterns during the early stage of the POLT-HCV-SVR trial, and their rapid market penetration is now expanding the trial-eligible population. The double-blind, placebo-controlled trial was initiated in May 2014 in patients with Ishak Fibrosis Scores of 2 to 4. Consistent with the company's initial registration focus on the development of a treatment for cirrhosis, the trial was expanded in early 2015 to include patients with Ishak 5 and is currently expanding to Ishak 6. Patients are being randomized 2:1 to receive either 25 mg of emricasan or placebo orally twice daily for 24 months and will be followed for another month post-treatment. The primary endpoint in this exploratory proof-of-concept trial is the change in the Ishak Fibrosis Score compared with placebo. The trial will also evaluate histological markers of inflammation, key serum biomarkers, and the safety and tolerability of emricasan in the target patient population. Enrollment of approximately 60 total planned patients is on track for release of final top-line results in the first half of 2018.
June 24, 2015
09:11 EDTAMCCApplied Micro an affordable target for Qualcomm, says Summit Research
Subscribe for More Information
07:19 EDTLADRDeutsche Bank to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use